AB SCIEX (Framingham, Massachusetts, USA), a leader in the liquid chromatography-mass spectrometry industry, and Dalton Chemical Laboratories, Inc., o/a Dalton Pharma Services s (Toronto, Canada), a GMP contract manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries, including custom conjugation services and the development of antibody-drug conjugates (ADCs), announced today a research collaboration to further develop Antibody-Drug Conjugate (ADC) analysis capabilities. This collaboration includes the development of a more definitive and comprehensive method for the identification of drug loading and position of conjugation on macromolecules. Furthermore, the collaboration is expected to help bring more targeted antibody-based therapies to market faster.

From concept to market
The collaboration, which provides AB Sciex with the specialized synthetic conjugation capabilities of Dalton, is expected to help bring drugs from concept to market faster.

The research includes the preparation and characterization of ADC’s by Dalton scientists working with AB SCIEX experts to develop standardized analytical procedures on the TripleTOF® 5600+ system with SelexION™ technology and the new TripleTOF® 6600 platform for determining the chemical structures of conjugated molecules.

“A key challenge for developing successful Antibody-Drug Conjugate medicines is understanding the structure and payload of the final molecule. Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC,” noted Tan Quach, Chemistry Manager at Dalton Pharma Services.

Advertisement #3 

“Recent advances in mass spectrometry have provided a solution to answer the challenging questions in terms of understanding ADC drug development and working within a biological matrix,” explained Chris Radloff, Vice President, LC/ MS Business at AB SCIEX. “Utilizing these molecules is difficult and by forming this partnership, ADC developers can now reduce complications, and obtain accurate results that will ultimately lead to safer, more effective therapies.”

Results of the first phase of the collaboration were featured at 62nd ASMS Conference on Mass Spectrometry and Allied Topics, which was being held in Baltimore, June 15 – 19, 2014.

As part of the new partnership, the companies are expected to continue to co-develop standardized analytical procedures utilizing the Mass Spectrometry technology that delivers consistent results when compared with ELISA and publish technical papers over the next upcoming months.

Published in: Dalton Pharma Services, Inc and AB SCIEX, Inc websites

Advertisement #4